Astra Wealth Partners LLC Invests $272,000 in Axon Enterprise, Inc $AXON

Astra Wealth Partners LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 329 shares of the biotechnology company’s stock, valued at approximately $272,000.

Several other institutional investors and hedge funds have also made changes to their positions in AXON. Jennison Associates LLC raised its position in shares of Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after buying an additional 611,418 shares during the period. Nuveen LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at approximately $264,796,000. McElhenny Sheffield Capital Management LLC purchased a new stake in shares of Axon Enterprise during the 2nd quarter valued at approximately $255,833,000. Westfield Capital Management Co. LP raised its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after buying an additional 212,931 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after buying an additional 185,571 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $732.23 on Monday. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $731.05 and a two-hundred day simple moving average of $733.88. The company has a market cap of $57.48 billion, a price-to-earnings ratio of 180.80, a price-to-earnings-growth ratio of 29.49 and a beta of 1.41. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.20 earnings per share. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the completion of the transaction, the chief executive officer owned 3,053,982 shares in the company, valued at approximately $2,538,744,696.78. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Hadi Partovi acquired 1,358 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was bought at an average price of $740.00 per share, with a total value of $1,004,920.00. Following the purchase, the director directly owned 237,938 shares of the company’s stock, valued at $176,074,120. This represents a 0.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 59,932 shares of company stock valued at $45,115,616. Insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. lifted their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. JMP Securities reissued a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a research report on Monday, September 29th. Finally, UBS Group reissued a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.